Literature DB >> 14630398

Incomplete Th2 skewing of cytokines in plasma of patients with squamous cell carcinoma of the head and neck.

Deanne M R Lathers1, Nicholas J Achille, M Rita I Young.   

Abstract

Levels of cytokines, and in particular those that reflect Th1 or Th2 bias, were measured in the plasma of patients with head and neck squamous cell carcinomas (HNSCC). Compared with plasma cytokine levels of age-matched controls, cytokine levels in HNSCC patients suggested a shift to a Th2 bias as levels of the Th2 cytokines interleukin-4 (IL-4), IL-6, and IL-10 were increased, and levels of the Th1 cytokine interferon-gamma (IFN-gamma) were decreased. However, levels of the Th1 cytokines IL-2 and granulocyte macrophage-colony-stimulating factor (GM-CSF) were increased, which is not consistent with full Th2 skewing. Assessment of cytokine levels in patients with malignancies other than HNSCC demonstrated many similarities to HNSCC patients, but HNSCC patients exhibited a more pronounced increase in GM-CSF levels and a decline in IFN-gamma levels. For most cytokines there was no association between the shifts in cytokine levels in HNSCC patients and either the extent of tumor burden or extent of metastasis. However, patients with large HNSCC tended to be the population that demonstrated increased levels of IL-4 and IL-6. These results suggest skewing toward a Th2 bias in HNSCC patients, with the Th2 shift being incomplete and indicative of the presence, rather than the extent, of malignant disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14630398     DOI: 10.1016/j.humimm.2003.08.024

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  21 in total

1.  Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients.

Authors:  Anamika Bose; Tathagata Chakraborty; Krishnendu Chakraborty; Smarajit Pal; Rathindranath Baral
Journal:  Cancer Immun       Date:  2008-06-12

2.  Use of alpha,25-dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma.

Authors:  Jarrett E Walsh; Anna-Maria Clark; Terry A Day; M Boyd Gillespie; M Rita I Young
Journal:  Hum Immunol       Date:  2010-05-16       Impact factor: 2.850

3.  Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes.

Authors:  Michael S Leibowitz; Pedro A Andrade Filho; Soldano Ferrone; Robert L Ferris
Journal:  Cancer Immunol Immunother       Date:  2011-01-05       Impact factor: 6.968

Review 4.  T-helper and T-regulatory cells modulation in head and neck squamous cell carcinoma.

Authors:  Daniele Maggioni; Lorenzo Pignataro; Werner Garavello
Journal:  Oncoimmunology       Date:  2017-05-04       Impact factor: 8.110

5.  Characterization of the evolution of immune phenotype during the development and progression of squamous cell carcinoma of the head and neck.

Authors:  Anna-Maria A De Costa; Corinne A Schuyler; David D Walker; M Rita I Young
Journal:  Cancer Immunol Immunother       Date:  2011-11-25       Impact factor: 6.968

6.  USC-HN2, a new model cell line for recurrent oral cavity squamous cell carcinoma with immunosuppressive characteristics.

Authors:  Sarah M Russell; Melissa G Lechner; Lucy Gong; Carolina Megiel; Daniel J Liebertz; Rizwan Masood; Adrian J Correa; Jing Han; Raj K Puri; Uttam K Sinha; Alan L Epstein
Journal:  Oral Oncol       Date:  2011-06-29       Impact factor: 5.337

7.  Tumors induce the formation of suppressor endothelial cells in vivo.

Authors:  Jennifer Konopa Mulligan; M Rita I Young
Journal:  Cancer Immunol Immunother       Date:  2010-02       Impact factor: 6.968

8.  Use of carcinogen-induced premalignant oral lesions in a dendritic cell-based vaccine to stimulate immune reactivity against both premalignant oral lesions and oral cancer.

Authors:  M Rita I Young
Journal:  J Immunother       Date:  2008 Feb-Mar       Impact factor: 4.456

9.  Secretion of vascular endothelial growth factor by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functions.

Authors:  Jennifer K Mulligan; Terry A Day; M Boyd Gillespie; Steven A Rosenzweig; M Rita I Young
Journal:  Hum Immunol       Date:  2009-02-12       Impact factor: 2.850

10.  A list of candidate cancer biomarkers for targeted proteomics.

Authors:  Malu Polanski; N Leigh Anderson
Journal:  Biomark Insights       Date:  2007-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.